Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS

TOKYO, May 27, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression

Related Keywords

Tokushima ,Japan ,Tokyo , ,Eisai Co Ltd ,Tokushima University ,Department Of Neurology ,Tokushima University Graduate School Of Biomedical Sciences ,Public Relations Department ,Ministry Of Health ,Japan Early Stage Trial ,Ultrahigh Dose Methylcobalamin ,Extraordinary Professor Ryuji Kaji ,Principal Investigator ,Professor Yuishin Izumi ,Coordinating Investigator ,Tokushima University Graduate School ,Biomedical Sciences ,Relations Department ,Eisai ,Mhlw ,Migrants ,Orphan ,Drug ,Resignation ,Ecobalamin ,Ultrahigh ,Nose ,Formulation ,Prospective ,Indication ,Delaying ,Progression ,Disease ,Unctional ,Impairment ,